Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240.

Authors

Paolo Milani^{1

2}, Stefan Schönland³, Giovanni Palladini^{1

2}, Christoph Kimmich³, Marco Basset^{1

2}, Francesca Russo^{1

2}, Andrea Foli^{1

2}, Stefano Perlini^{1

2}, Tilmann Bochtler³, Anthony D Ho³, Giampaolo Merlini^{1

2}, Ute Hegenbart³

Affiliations

¹ a Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo , Pavia , Italy.
² b Department of Molecular Medicine , University of Pavia , Pavia , Italy , and.
³ c Amyloidosis Center, University Hospital Heidelberg , Heidelberg , Germany.

PMID: 28434298
DOI: 10.1080/13506129.2017.1292240

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents, Alkylating / therapeutic use*
Bendamustine Hydrochloride / therapeutic use*
Female
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy
Immunoglobulin Light-chain Amyloidosis / mortality*
Immunoglobulin Light-chain Amyloidosis / pathology
Male
Prognosis
Recurrence
Retrospective Studies
Salvage Therapy*
Survival Rate

Substances

Antineoplastic Agents, Alkylating
Bendamustine Hydrochloride